Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral GLP-1 pill being studied for the treatment of type 2 diabetes and obesity, ...

(CNN) — The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday.

Ozempic Insulin box and injection pen or insulin cartridge pen for diabetes patients from Novo Nordisk. Blurred pharmacy background. Copenhagen, Denmark - January 29, 2024. A semaglutide pill is ...

A new oral GLP-1 receptor agonist, orforglipron, is revolutionizing weight management by offering a needle-free alternative ...

An oral weight loss pill has performed well in clinical trials, positioning it as a potential alternative to injectable GLP-1 medications like Ozempic and Wegovy. The Eli Lilly drug, called ...

So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with *** lower risk of ...

Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday.